Bendamustine and rituximab combination in the management of chronic lymphocytic leukemia‐associated autoimmune hemolytic anemia: A multicentric retrospective study of the French CLL intergroup (GCFLLC/MW and GOELAMS). Issue 3 (16th January 2015)

• Record Type: Journal Article
• Authors: Quinquenel, Anne; Willekens, Christophe; Dupuis, Jehan; Royer, Bruno; Ysebaert, Loic; Guibert, S. De; Michallet, Anne‐Sophie; Feugier, Pierre; Guieze, Romain; Levy, Vincent; Delmer, Alain
• Is Part Of: American journal of hematology. Volume 90:Issue 3(2015:Mar.)
• Page Start: 204
• Page End: 207
• Publication Date: 2015-01-16
• Subjects: Hematology -- Periodicals; 616.15
• DOI: 10.1002/ajh.23909
• Languages: English
• ISSNs: 0361-8609

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <p>We report our experience on bendamustine and rituximab (BR) combination in 26 patients with chronic lymphocytic leukemia (CLL) complicated by autoimmune hemolytic anemia (AIHA). At the time of BR initiation, 88% of the patients had already been treated for AIHA and CLL was progressive regardless of AIHA in all patients but one. Overall response rates were 81% for AIHA and 77% for CLL. Median time to next treatment was 28.3 months and 26.2 months for AIHA and CLL, respectively. BR therapy may represent a good and safe therapeutic option in this setting where adequate control of CLL seems important for long‐term AIHA response. Am. J. Hematol. 90:204–207, 2015. © 2014 Wiley Periodicals, Inc.</p> </abstract>